| Objective:In this study,the circulating cell-free DNA(cfDNA)concentration in plasma of women with ovarian cancer was determined and analyzed to explore the application value of cfDNA in screening and diagnosis of ovarian cancer.The diagnostic efficacy of cfDNA in ovarian cancer was evaluated by comparing it with carbohydrate antigen 125(CA125).To seek a noninvasive,accurate,convenient and effective method for the clinical diagnosis of ovarian cancer in the future.Methods:A case-control study was used in this study.A total of 59 patients with ovarian cancer diagnosed by clinicopathological examination admitted to Baoding NO.1 Central Hospital from September 2019 to December 2020 were collected as the ovarian cancer group,50 patients with other benign ovarian tumors hospitalized during the same period were selected as the benign ovarian tumor group,and 50 healthy adult females who underwent physical examination in Baoding NO.1 Central Hospital during the same period were selected as the healthy group.Blood samples of the three groups of subjects were collected.Blood samples of the ovarian cancer group and the ovarian benign tumor group were collected on the first day of admission to separate the plasma of all blood samples,and cfDNA was extracted from the plasma.The purified cfDNA was detected by fluorescence PCR,and the specific content was obtained according to the results.The basic data of the study group and the two control groups were compared,and the data of the three groups were statistically analyzed.By comparing the difference in the total concentration of cfDNA in blood of the three groups of subjects and the difference in the concentration of cfDNA in ovarian cancer of different types and stages in the ovarian cancer group,useing the ROC curve to calculate the specificity and sensitivity of cfDNA.Results:1.Meidan cfDNA concentration in ovarian cancer patients:97.20(53.34-151.58)ng/m L,Median cfDNA concentration in benign ovarian tumor patients: 8.45(4.69-24.57)ng/m L.Median cfDNA concentration in healthy adult females: 9.44(2.50-20.42)ng/m L.The cfDNA concentration in the ovarian cancer group was significantly higher than that in the benign ovarian tumor group and the healthy group,and the difference between groups was statistically significant(P<0.05).There was no statistically significant difference in cfDNA concentration between the benign ovarian tumor group and the healthy group(P >0.05).2.According to FIGO surgical-pathological staging,Median cfDNA concentration in stage I ovarian cancer patients: 41.51(20.41-90.34)ng/m L,stage Ⅱ: 97.20(61.56-110.96)ng/m L,stage Ⅲ: 151.98(107.46-208.51)ng/m L,stage Ⅳ: 372.71(341.57-549.16)ng/m L.The cfDNA level in early ovarian cancer(stage I-Ⅱ)was significantly lower than that in late ovarian cancer(stageⅢ-Ⅳ),and the difference was statistically significant(P <0.05).3.Median cfDNA concentration in epithelial ovarian cancer:99.38(40.56-145.56)ng/m L,nonepithelial ovarian cancer:97.20(66.67-208.45)ng/m L,There was no statistical difference in cfDNA concentration among different histopathological types(P >0.05).4.According to the ROC curve,the cut-off values for cfDNA is48.08ng/m L,the AUC,sensitivity and specificity of cfDNA in the ovarian cancer group were 0.906,79.0% and 85.0%.Blood levels of CA125 were also measured for all study subjects,the AUC,sensitivity and specificity of CA125 in the ovarian cancer group were 0.774,76.3% and 69.0%.Cf DNA levels combined with CA125 can improve the AUC,sensitivity and specificity to0.929,84.7% and 91.0%.Conclusion:1.The plasma cfDNA concentration of ovarian cancer patients is higher than that of healthy women.It is believed that the quantitative detection of cfDNA has certain clinical value in the diagnosis of ovarian cancer,and is expected to be an accurate,convenient and reliable tumor marker for the diagnosis of ovarian cancer in the future.2.The plasma cfDNA concentration of advanced ovarian cancer patients is higher than that of early ovarian cancer patients,suggesting that the level of cfDNA may increase with the development of the disease.3.The diagnostic efficacy of cfDNA concentration for ovarian cancer is higher than CA125,cf-DNA levels combined with CA125 can improve the diagnostic efficacy. |
PDF Full Text Request